Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

In this article, we are going to take a look at where Exelon Corporation (NASDAQ:EXC) stands against the other dividend stocks. Stable income, offered by the dividend stocks, has historically ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bank of Montreal (BMO) announced 10 new CDRs will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed. Ad hoc announcement pursuant to Art. 53 LRFull ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF110.00. Leverage the power of TipRanks' Smart Score ...

Am J Health Syst Pharm. 2012;69(2):116-124. For this article, information on about three dozen currently available TDDS products commonly encountered in clinical practice was compiled through a ...